Colchicine for Symptom and Inflammation in Knee Osteoarthritis
Status:
Completed
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Uric acid may be involved in the activation of the innate immune response in osteoarthritis
(OA) pathology and progression. This suggests that traditional gout therapy may be beneficial
for OA. Our goal therefore is to assess colchicine, an existing commercially available agent
for gout, for a new therapeutic indication-knee OA. The investigators propose a randomized
clinical trial (RCT) of 16 weeks' therapy with standard daily dose oral colchicine or placebo
for knee OA. The investigators hypothesize that colchicine will block inflammasome mediated
inflammation, thereby improve the signs and symptoms of OA, and reduce synovial fluid, serum
and urine inflammatory and biochemical joint degradation biomarkers. This trial will
potentially provide data to support a new treatment option for knee OA.